High Tide Hits 7.6 Tonne Record in German Medical Cannabis Market

High Tide Inc. (NASDAQ: HITI) delivered a record quarterly performance through its German medical cannabis operations, with subsidiary Remexian Pharma GmbH distributing 7.6 tonnes of medical cannabis products. The distribution volume represents a substantial increase in the company's European footprint and validates its strategic pivot toward higher-margin medical cannabis markets outside North America.

Germany's medical cannabis market continues expanding rapidly following legislative reforms that streamlined patient access and physician prescribing protocols. The country now ranks among Europe's largest medical cannabis markets by volume, with annual consumption exceeding 25 tonnes across all licensed distributors. High Tide's 7.6 tonne quarterly performance positions Remexian Pharma as a major player in this growing ecosystem, capturing meaningful market share in a region where regulatory barriers remain lower than recreational cannabis markets.

The record distribution numbers arrive as High Tide restructures its business model away from retail-heavy operations that dominated its Canadian roots. European medical cannabis operations typically generate higher gross margins than North American retail, with wholesale distribution margins ranging from 15-25% compared to single-digit retail margins in saturated markets like Canada. This shift toward B2B medical distribution provides more predictable revenue streams and reduced regulatory risk.

Remexian Pharma's performance reflects broader momentum in European medical cannabis adoption, where patient registrations continue climbing across key markets including Germany, Netherlands, and the UK. Germany's patient base exceeded 150,000 registered users in 2024, creating sustained demand for reliable distribution networks. High Tide's established infrastructure positions the company to capture additional market share as German medical cannabis consumption grows.

The German market expansion supports High Tide's international diversification strategy as North American cannabis markets face oversupply pressures and margin compression. European medical cannabis markets offer more stable regulatory frameworks and less competition from black market operators, creating better conditions for sustained profitability. High Tide's record quarterly distribution demonstrates the company's ability to execute on international growth while building scalable operations in premium cannabis markets.